OptiBiotix Health PLC Director's Dealing (6614V)
16 April 2021 - 4:00PM
UK Regulatory
TIDMOPTI
RNS Number : 6614V
OptiBiotix Health PLC
16 April 2021
Opti B i otix Health plc
( "Opti Bi o t ix" or the "Company")
Director's Dealing
OptiBi otix Health p lc (AI M : OPTI), a life sciences busi ness
d e vel o ping co m p o u n ds to tack le o besit y, high choleste
r ol, diabetes and skincare, announces that it received
notification on 15 April 2021 that Mr Stephen Hammond, a recently
appointed Non-Executive Director of the Company (RNS 2(nd) February
2021), acquired 25,000 ordinary shares in the Company on 15 April
2021, representing 0.03% of the Company's issued share capital, at
an average price of 51.8 pence per share.
Mr Hammond did not hold any ordinary shares in the Company prior
to the above transaction.
This announcement contains inside information for the purposes
of the UK Market Abuse Regulation and the Directors of the Company
are responsible for the release of this announcement.
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Neil Davidson, Chairman Contact via Walbrook
below
Stephen O'Hara, Chief Executive
Cairn Financial Advisers LLP (NOMAD) Tel: 020 7213 0880
Liam Murray / Jo Turner / Ludovico Lazzaretti
Cenkos Securities plc (Broker) Tel: 020 7397 8900
Callum Davidson / Neil McDonald
Michael Johnson / Russell Kerr (Sales)
Walbrook PR Ltd Mob: 07876 741 001
Anna Dunphy
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March
2012, brings science to the development of compounds which modify
the human microbiome - the collective genome of the microbes in the
body - in order to prevent and manage human disease and promote
wellness.
OptiBiotix has an extensive R&D programme working with
leading academics in the development of microbial strains,
compounds, and formulations which are used as active ingredients
and supplements. More than twenty international food and healthcare
supplement companies have signed agreements with OptiBiotix to
incorporate their human microbiome modulators into a wide range of
food products and drinks.
OptiBiotix is also developing its own range of consumer
supplements and health products. The Company's current areas of
focus include obesity, cardiovascular health, and diabetes.
Notification of a Transaction pursuant to Article 19(1) of Regulation
(EU) No. 596/2014
1 Details of the person discharging managerial responsibilities/person
closely associated
------------------------------------------------------------------------------------------
a. Name Stephen Hammond
---------------------------------------- ------------------------------------------------
2 Reason for notification
---------------------------------------- ------------------------------------------------
a. Position/Status Non-Executive Director
---------------------------------------- ------------------------------------------------
b. Initial notification/ Initial Notification
Amendment
---------------------------------------- ------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
------------------------------------------------------------------------------------------
a. Name OptiBiotix Health Plc
---------------------------------------- ------------------------------------------------
b. LEI 213800UKYQFT941QHS14
---------------------------------------- ------------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
------------------------------------------------------------------------------------------
a. Description of 25,000 ordinary shares of 2p each
the financial
instrument, type
of instrument
ISIN: GB00BP0RTP38
Identification
Code
---------------------------------------- ------------------------------------------------
b. Nature of the Purchase of 25,000 ordinary shares in the
transaction Company
---------------------------------------- ------------------------------------------------
c. Price(s) and volume(s) Price(s) per Volume(s)
share
---------------------------------------- --------------------------
51.8p 25,000
-------------------------- ----------------
d. Aggregated information
* Volume n/a
* Price
---------------------------------------- ------------------------------------------------
e. Date of the transaction 15 April 2021
---------------------------------------- ------------------------------------------------
f. Place of the transaction London Stock Exchange, AIM
---------------------------------------- ------------------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHBCGDSIXBDGBU
(END) Dow Jones Newswires
April 16, 2021 02:00 ET (06:00 GMT)
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Apr 2023 to Apr 2024
